propofol (Liposeuticals)

LSI-101 is a proprietary, lipid-based reformulation of the intravenous anesthetic **propofol**, developed by **LipoSeuticals**. It is designed for the induction and maintenance of **general anesthesia**. LSI-101 utilizes a stable, antimicrobial emulsion technology intended to improve the safety, stability, and tolerability profile compared to standard propofol emulsions (such as Diprivan). The active ingredient, propofol, acts primarily as a **positive allosteric modulator of the GABA-A receptor**, enhancing inhibitory neurotransmission in the central nervous system to produce sedation and anesthesia. LSI-101 is administered via **intravenous** injection and is currently in development as a potentially safer alternative to conventional propofol formulations.

Other names

propofol emulsionlipid-based propofol